**CLAIMS**

What is claimed is:

1. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament for treating a brain cancer in a subject in need, wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

2. The use of claim 1, wherein the medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

3. The use of claims 1 or 2, wherein the CPEVs are to be administered intranasally.

4. The use of any of claims 1-3, wherein the CPEVs are to be administered intranasally using a nasal delivery device selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a nasal spray bottle, a squeeze bottle and a bi-directional device.

5. The use of any of claims 1-4, wherein the medicament is to be co-administered with an adjunct cancer therapy protocol.

6. The use of claim 5, wherein the adjunct cancer therapy protocol comprising treating the mammal with radiation before, during, or after the administration of the CPEVs

7. The use of claim 5, wherein the adjunct cancer therapy protocol comprising an additional chemotherapeutic agent.

8. A composition comprising CPEVs and a pharmaceutically acceptable carrier.

9. The composition of claim 8, wherein the pharmaceutically acceptable carrier comprises an excipient for intranasal delivery.

10. A device comprising a container, wherein a CPEV composition is disposed within said container, and a spout associated with the container that is configured for insertion into a nostril of a subject in need.

11. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament for treating a neurodegenerative disease in a subject in need, wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

12. The use of claim 11, wherein the composition is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

13. The use of claim 11, wherein the neurodegenerative disease comprises stroke, Alzheimer's disease, ALS, MS, Parkinson's disease, traumatic brain injury, or aging.

14. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament for treating a CNS injury in a subject in need, wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

15. The use of claim 14, wherein the medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

16. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament for treating an inflammatory condition in a subject in need, wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

17. The use of claim 16, wherein the medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

18. Use of cannabinoid containing plant extracellular vesicles (CPEVs) in the manufacture of a medicament for augmenting function of a CNS in a subject, wherein a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs) is to be administered to the subject.

19. The use of claim 18, wherein the medicament is to be administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.

20. A method of making csPEVs comprising

obtaining PEVs from a Cannabis spp.; and

loading the PEVs with an exogenous payload.

21. A composition comprising csPEVs loaded with an exogenous payload.

22. A device comprising a container, wherein an amount of the composition of claim 21 is disposed within said container.

23. The device of claim 22, further comprising a spout associated with the container that is configured for insertion into a nostril of a subject in need.

24. The use of any of claims 1-7, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 ± 2.1%, 19.1 ± 1.6%, 6.5 ± 0.54%, 4.75 ± 0.26%, and 0.5 ± 0.3% of total cannabinoids, respectively.

25. A composition of claim 8, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 ± 2.1%, 19.1 ± 1.6%, 6.5 ± 0.54%, 4.75 ± 0.26%, and 0.5 ± 0.3% of total cannabinoids, respectively.

26. The use of any of claims 11-19, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 ± 2.1%, 19.1 ± 1.6%, 6.5 ± 0.54%, 4.75 ± 0.26%, and 0.5 ± 0.3% of total cannabinoids, respectively.